ClinicalTrials.gg
RecruitingNCT07455331LANCEUpdated Nov 17, 2026

Flash Radiotherapy for Skin Cancer

A Phase 2 interventional study of FLASH radiotherapy and Conventional radiotherapy in Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC), sponsored by Jules Bordet Institute. Recruiting at 1 site in Belgium. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Jules Bordet Institute · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Carcinoma, Basal Cell with a site in Belgium — 2 open to participants now, 2 under way, none of them phase 3. Carcinoma, Basal Cell · Belgium.

Planned enrollment
9th of 12
60 · median 107
Started
2026
the only one that year
Phase 2
6 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Jules Bordet Institute

Among the 14 studies in Carcinoma, Basal Cell with a site in Belgium, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 6 in phase 2, and was the 14th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

2 of the 14 studies in Carcinoma, Basal Cell with a site in Belgium are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Carcinoma, Basal Cell with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this clinical investigation is to describe and compare the toxicity and efficacy of an experimental radiotherapy, named FLASH therapy, to conventional radiotherapy for subjects suffering from localized Cutaneous Squamous Cell Carcinoma (cSCC) and Basal Cell Carcinoma (BCC). FLASH therapy can deliver the irradiation dose within milliseconds instead of the minutes commonly required in conventional radiotherapy, with the aim of providing a curative dose while minimizing side effects on healthy tissue.

This is a phase II selection and monocentric clinical investigation with a 1 to 1 randomization. This clinical investigation will include approximately 60 participants aged ≥ 60 years old with one or more localized cSCC and BCC who either cannot undergo surgery or decline surgical resection.

The study design is the following:

  • On day 1, either a single dose FLASH radiotherapy (22 Gy) will be delivered or a single dose conventional radiotherapy (22 Gy) will be delivered to the selected localized cSCC or BCC lesion(s) (up to maximum 3 per participant; all lesions distant of at least 4 cm from one-another).
  • The surveillance period will be of 6 weeks post irradiation.
  • Follow-up visits will take place at 3, 6, and 12 months post-treatment.
03

Conditions studied

  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Basal Cell Carcinoma (BCC)

Keywords

  • radiotherapy
  • FLASH
  • skin cancer
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed study Form
  2. Performance Status (KPS) ≥ 60
  3. Age ≥ 60 years
  4. Participants with proven cSCC; or participants with BCC either histologically proven or proven by non-invasive imaging: either OCT, LC-OCT or RCM
  5. Participants requiring radiotherapy treatment according to the dermato-oncology tumor board: participants who cannot undergo surgical procedure or participants who decline surgical resection, and/or anatomical locations where surgery can compromise function or cosmesis.
  6. T1-N0 lesions (TNM UICC, 8th Edition)
  7. Lesions should be at least 4 cm apart if treated with 2 different modalities (including surgical treatment of lesions). Lesions should not be located on the face, except on the forehead, above a line situated 1 cm above the eyebrows. Lesions located on the scalp can be treated
  8. In cases of prior intervention within the target area, the treated lesion must be located at a distance of > 4 cm from the previous site.

Exclusion criteria

Exclusion Criteria:

  1. Previous radiotherapy in the treated area or a history of radiation therapy within 4 cm of the lesion to be treated
  2. Concomitant auto-immune disease with skin lesions
  3. Concomitant use of radio-sensitizer drug
  4. Cognitive disorders not compatible with the signature of or that may compromise compliance with the requirements of the study
  5. Current, recent (within 10 days prior to start of study treatment), or planned participation in an experimental drug study (before EOT visit)
  6. Concomitant use of systemic or immunochemotherapy for skin cancer(s)
  7. Concomitant use of systemic chemotherapy for a cancer other than the skin cancer(s)
  8. Topical antitumoral treatment is prohibited within the radiation field except after a mandatory 4-weeks .
  9. Any active cutaneous infection within the irradiation field (except if completely resolved prior to the initiation of radiotherapy).
  10. Uncontrolled intercurrent comorbidities that may impair wound healing including Diabetes Mellitus ( > 8.5% or evidence of active diabetic ulceration), Chronic Venous Insufficiency with active venous ulcers, or severe (Grade 3+) oedema in the treatment field.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    FLASH radiotherapy

    22 Gy single dose FLASH radiotherapy

    Radiation: FLASH radiotherapy

  • Active comparator
    Conventional radiotherapy

    22 Gy single dose conventional radiotherapy

    Radiation: Conventional radiotherapy

Interventions

  • RadiationFLASH radiotherapy

    FLASH therapy is delivered almost instantaneously (in milliseconds), as opposed to conventional radiotherapy, which is delivering the dose in minutes.

  • RadiationConventional radiotherapy

    Standard of Care

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of FLASH radiotherapy

    Safety of FLASH radiotherapy measured by the collection of ≥ grade 3 skin toxicity AEs (CTCAE v6.0) ≤ 6 weeks after radiotherapy. Assessment will be performed by physical examination at 3,4,6 weeks post treatment (It may be necessary to perform these procedures at unscheduled time points if deemed clinically necessary by the investigator).

    Time frame: "From enrollment until 6 weeks after radiotherapy"

  2. hierarchically tested efficacy of FLASH radiotherapy

    Hierarchically tested efficacy measured by local control rate at 1-year. Local control rate is censured by any in field local relapse up to one-year post randomization (Tumor response evaluated during physical exam). Assessment will be performed by physical exam and Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks and 3,6,12 months.

    Time frame: "From enrollment until 1-year post randomization"

Secondary outcomes

  1. Evaluate tumor response

    Tumor response Assessment will be performed by physical exam and Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks and 3,6,12 months post treatment

    Time frame: "From enrolment until 12 months post-treatment"

  2. Evaluate acute side effects "in the radiation field"

    Acute side effects "in the radiation field" defined by any toxicity (CTCAE v6.0), until 3 months after the irradiation date. Assessment will be performed by physical exam, Blinded Imaging Central Review (BICR) of photographs at 3,4,6 weeks post treatment and OCT (optical coherence tomography) at 4 weeks post treatment.

    Time frame: "From enrollment until 6 weeks after the irradiation date"

  3. Evaluate late side effects "in the radiation field"

    Late side effects "in the radiation field" (within 3 to 12 months post-treatment) (CTCAE v6.0). Assessment will be performed by physical exam, Blinded Imaging Central Review (BICR) of photographs 3,6,12 months post treatment and OCT (optical coherence tomography) at 6 and 12 months.

    Time frame: "From 3 months post treatment until 12 months post treatment"

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 39 months after the start.

Of 44 phase 2 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 67. This study's planned 39 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Mar 6, 2026
StartActual
Aug 24, 2026was Jun 2026
Primary completionEst.
Dec 23, 2029
CompletionEst.
Dec 23, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
Institut Jules Bordet is now Recruiting
Nov 17, 2026
Start date
Jun 23, 2026→Aug 24, 2026 (actual)
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Institut Jules Bordet · Brussels, BelgiumContact added a•••@hubruxelles.be · •••3032
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    Institut Jules Bordet is now Recruiting
    Start date Jun 23, 2026→Aug 24, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Institut Jules Bordet · Brussels, BelgiumContact added a•••@hubruxelles.be · •••3032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07455331
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Aug 24, 2026
Primary completion
Dec 23, 2029 (estimated)
Completion
Dec 23, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Antoine Desmet, Dr
Contact
antoine.desmet@hubruxelles.be
+32 2 5413032
Sophie Lepannetier, PhD
Contact
sophie.lepannetier@hubruxelles.be
+32 02 541 3456

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion